[go: up one dir, main page]

CR9267A - Derivados de quinazolina para el tratamiento de la tuberculosis latente - Google Patents

Derivados de quinazolina para el tratamiento de la tuberculosis latente

Info

Publication number
CR9267A
CR9267A CR9267A CR9267A CR9267A CR 9267 A CR9267 A CR 9267A CR 9267 A CR9267 A CR 9267A CR 9267 A CR9267 A CR 9267A CR 9267 A CR9267 A CR 9267A
Authority
CR
Costa Rica
Prior art keywords
treatment
latent tuberculosis
alkyl
quinazoline derivatives
compound
Prior art date
Application number
CR9267A
Other languages
English (en)
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Anil Koul
Original Assignee
Jannsen Pharmaceutica N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35717702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9267(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jannsen Pharmaceutica N V filed Critical Jannsen Pharmaceutica N V
Publication of CR9267A publication Critical patent/CR9267A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de un compuesto de la formula (la) o (lb) para la fabricacion de un medicamento para el tratamiento de la tuberculosis latente, en donde el compuesto de formula (la) o (lb) es una sal farmaceuticamente aceptable, una amina cuaternaria, un N-oxido, una forma tautomera o una forma estereoquimicamente isomerica de los mismos en donde R1 es hidrogeno, halo, haloalquilo, ciano, hidroxi, Ar, Het, alquilo, alquiloxi, alquiltio, alquiloxialquilo, alquiltioalquilo, Ar-alquilo o di(Ar)alquilo; p es un numero entero igual a 1, 2, 3, o 4.
CR9267A 2004-12-24 2007-07-20 Derivados de quinazolina para el tratamiento de la tuberculosis latente CR9267A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04078529 2004-12-24
EP05105008 2005-06-08

Publications (1)

Publication Number Publication Date
CR9267A true CR9267A (es) 2008-09-09

Family

ID=35717702

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9267A CR9267A (es) 2004-12-24 2007-07-20 Derivados de quinazolina para el tratamiento de la tuberculosis latente

Country Status (30)

Country Link
US (1) US20060142279A1 (es)
EP (1) EP1830850B1 (es)
CN (1) CN103142595B (es)
AP (1) AP2327A (es)
AR (1) AR051790A1 (es)
AT (1) ATE501721T1 (es)
AU (1) AU2005242138B2 (es)
BR (1) BRPI0506400B8 (es)
CA (1) CA2529265C (es)
CR (1) CR9267A (es)
CY (1) CY1112247T1 (es)
DE (1) DE602005026984D1 (es)
DK (1) DK1830850T3 (es)
EE (1) EE05394B1 (es)
HR (1) HRP20110392T1 (es)
IL (1) IL184123A (es)
LV (1) LV13469B (es)
ME (1) ME01207B (es)
MY (1) MY145845A (es)
NI (1) NI200700146A (es)
NO (1) NO340376B1 (es)
NZ (1) NZ555460A (es)
PA (1) PA8654801A1 (es)
PL (1) PL1830850T3 (es)
PT (1) PT1830850E (es)
RS (1) RS51730B (es)
SI (1) SI1830850T1 (es)
TR (1) TR200504892A1 (es)
TW (1) TWI404535B (es)
WO (1) WO2006067048A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0312927B8 (pt) * 2002-07-25 2021-05-25 Janssen Pharmaceutica Nv "compostos, derivados de quinolina, composição, seu uso como inibidores micobacteriais, bem como processo para preparação dos referidos derivados".
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
PT1898909T (pt) * 2005-06-28 2016-12-07 Janssen Pharmaceutica Nv Derivados de quinolina como agentes antibacterianos
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
WO2009091324A1 (en) * 2008-01-14 2009-07-23 Jyoti Chattopadhyaya Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivates as anti-mycobacterial agents
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
EP2387564A1 (en) 2009-01-15 2011-11-23 Rutgers, The State University of New Jersey Benzo ýc¨phenanthridines as antimicrobial agents
CA2760526A1 (en) 2009-04-30 2010-11-04 Rutgers, The State University Of New Jersey Antimicrobial agents
CA2810162A1 (en) 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
US9102617B2 (en) 2010-06-25 2015-08-11 Rutgers, The State University Of New Jersey Antimicrobial agents
US9822108B2 (en) 2012-01-13 2017-11-21 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2013142712A1 (en) 2012-03-21 2013-09-26 Rutgers, The State University Of New Jersey Antimicrobial agents
US9617244B2 (en) 2012-04-27 2017-04-11 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
ES2576491T3 (es) 2012-04-27 2016-07-07 Janssen Pharmaceutica, N.V. Derivados de quinolina antibacterianos
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
PL3250182T3 (pl) 2015-01-27 2023-07-31 Janssen Pharmaceutica Nv Kompozycje dyspergowalne
JP2019507801A (ja) 2016-02-25 2019-03-22 タクシス ファーマシューティカルズ， インコーポレイテッド 合成プロセス及び中間体
BR122023025283A2 (pt) 2016-03-07 2024-02-20 Global Alliance For Tb Drug Development Inc Compostos antibacterianos e seus usos
RU2629369C1 (ru) * 2016-10-05 2017-08-29 Федеральное Государственное Унитарное Предприятие "Государственный Ордена Трудового Красного Знамени Научно-Исследовательский Институт Химических Реактивов И Особо Чистых Химических Веществ" Четвертичные аммонийные производные 2-аминотиофен-3-карбоксилатов, обладающие противотуберкулезной активностью
US10774093B2 (en) 2017-03-30 2020-09-15 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates
JP7102500B2 (ja) 2017-07-14 2022-07-19 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
RU2661151C1 (ru) * 2017-12-14 2018-07-12 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Селективные ингибиторы глицеральдегид-3-фосфатдегидрогеназы микобактерий
CN113271930A (zh) 2019-01-09 2021-08-17 詹森药业有限公司 治疗非结核分枝杆菌疾病的组合
US20230355606A1 (en) 2020-07-09 2023-11-09 Janssen Pharmaceutica Nv Long-acting formulations
US20230241051A1 (en) 2020-07-09 2023-08-03 Janssen Pharmaceutica Nv Long-acting formulations
EP4243800A1 (en) 2020-11-12 2023-09-20 JANSSEN Pharmaceutica NV Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2025068448A1 (en) 2023-09-28 2025-04-03 Janssen Pharmaceutica Nv Atp synthase inhibitors for use in the treatment of non-tuberculosis mycobacteria

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038536A1 (es) * 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
BRPI0312927B8 (pt) * 2002-07-25 2021-05-25 Janssen Pharmaceutica Nv "compostos, derivados de quinolina, composição, seu uso como inibidores micobacteriais, bem como processo para preparação dos referidos derivados".

Also Published As

Publication number Publication date
AU2005242138A1 (en) 2006-07-13
NO340376B1 (no) 2017-04-10
TWI404535B (zh) 2013-08-11
HRP20110392T1 (hr) 2011-06-30
EE05394B1 (et) 2011-04-15
US20060142279A1 (en) 2006-06-29
CA2529265A1 (en) 2006-06-24
CN103142595A (zh) 2013-06-12
PA8654801A1 (es) 2006-08-03
CY1112247T1 (el) 2015-12-09
AR051790A1 (es) 2007-02-07
NI200700146A (es) 2019-05-10
DE602005026984D1 (de) 2011-04-28
AU2005242138B2 (en) 2011-05-26
SI1830850T1 (sl) 2011-07-29
MY145845A (en) 2012-04-30
NO20073823L (no) 2007-07-23
WO2006067048A1 (en) 2006-06-29
DK1830850T3 (da) 2011-06-14
AP2007004054A0 (en) 2007-06-30
TR200504892A1 (tr) 2010-04-21
BRPI0506400A8 (pt) 2017-09-12
HK1186125A1 (en) 2014-03-07
TW200637551A (en) 2006-11-01
RS51730B (sr) 2011-10-31
BRPI0506400B8 (pt) 2021-05-25
CA2529265C (en) 2014-02-11
EE200500033A (et) 2006-08-15
EP1830850B1 (en) 2011-03-16
IL184123A (en) 2011-10-31
ME01207B (me) 2013-03-20
LV13469B (en) 2007-01-20
CN103142595B (zh) 2015-05-06
PL1830850T3 (pl) 2011-07-29
BRPI0506400B1 (pt) 2021-04-06
ATE501721T1 (de) 2011-04-15
NZ555460A (en) 2008-11-28
BRPI0506400A (pt) 2006-08-29
PT1830850E (pt) 2011-05-31
EP1830850A1 (en) 2007-09-12
AP2327A (en) 2011-11-25
IL184123A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
CR9267A (es) Derivados de quinazolina para el tratamiento de la tuberculosis latente
GB201201744D0 (en) Novel compounds
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2009035004A1 (ja) 置換イソキサゾリン化合物および有害生物防除剤
AR064965A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
EA200602058A1 (ru) Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
SG196826A1 (en) Combinations comprising methotrexate and dhodh inhibitors
WO2009072621A1 (ja) 置換ジヒドロアゾール化合物及び有害生物防除剤
WO2008005368A3 (en) Piperazines as p2x7 antagonists
EP2597088A4 (en) P2X4 Receptor Antagonists
NZ593110A (en) pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
TW200738641A (en) Pyrazole based LXR modulators
WO2007117465A3 (en) Indazole compounds
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
NO20085087L (no) Nye heterocykliske forbindelser
SE0202463D0 (sv) Novel compounds
AR064026A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
PT2421879E (pt) Novos 7-deazapurina nucleósidos para utilizações terapêuticas
AR063805A1 (es) Derivados de triazol sustituidos como inhibidores de ksp. composiciones farmaceuticas.
BRPI0415053A (pt) inibidor de p-glicoproteìna, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
MX2008016558A (es) Preparacion y aplicacion terapéutica de derivados de 2-benzoil-imidazopiridinas.
UY27979A1 (es) Indoles sustituidos en posición 2,4
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma

Legal Events

Date Code Title Description
FC Refusal